Cumberland Pharma looking to gin $115M in IPO

Cumberland Pharmaceuticals has joined the list of developers looking to raise money in an IPO. Cumberland filed SEC papers for an offering designed to raise $115 million. UBS Investment Bank and Jefferies & Co. are leading the deal's underwriting. The Nashville-based company says it may use some of the money for new acquisitions. Its strategy has been to acquire approved or late-stage therapies. Cumberland also runs a life sciences incubator.

- read Cumberland's release
- here's the report on the IPO from the Nashville Business Journal

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.